Growth Metrics

Lexicon Pharmaceuticals (LXRX) Amortization of Deferred Charges (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Amortization of Deferred Charges for 3 consecutive years, with $495000.0 as the latest value for Q4 2025.

  • Quarterly Amortization of Deferred Charges rose 23.44% to $495000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, down 7.86% year-over-year, with the annual reading at $1.7 million for FY2025, 7.86% down from the prior year.
  • Amortization of Deferred Charges for Q4 2025 was $495000.0 at Lexicon Pharmaceuticals, up from $402000.0 in the prior quarter.
  • The five-year high for Amortization of Deferred Charges was $618000.0 in Q3 2023, with the low at $265000.0 in Q1 2023.
  • Average Amortization of Deferred Charges over 3 years is $443250.0, with a median of $402000.0 recorded in 2024.
  • Peak annual rise in Amortization of Deferred Charges hit 95.09% in 2024, while the deepest fall reached 35.11% in 2024.
  • Over 3 years, Amortization of Deferred Charges stood at $618000.0 in 2023, then tumbled by 35.11% to $401000.0 in 2024, then grew by 23.44% to $495000.0 in 2025.
  • According to Business Quant data, Amortization of Deferred Charges over the past three periods came in at $495000.0, $402000.0, and $402000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.